Results from a genome-wide functional screen to identify genes whose overexpression confers resistance to FGFR inhibitors in a FGFR1-amplified NSCLC cell line identified known resistance drivers such as MET, EGFR, AKT and MAPK, but also novel resistance mediators such as members of the neurotrophin receptor pathway (NTRKs) and the TAM family of tyrosine kinases (TYRO3, MERTK, AXL) [131]. This evidence concerns the gene MET and non-small cell lung carcinoma.